The role and interaction of bacteria in the lungs of cystic fibrosis patients is a key factor in the progression of the disease and the success of treatment, especially during chronic infections. Dr. Tony-Odigie and his team discovered that beneficial bacteria, isolated from the lungs, can inhibit the growth of harmful bacteria through their metabolic products. “We were able to show for the first time that beneficial bacteria isolated from the sputum of cystic fibrosis patients can suppress the growth of pathogenic bacteria by producing short-chain fatty acids such as acetate,” says Dr. Tony-Odigie, referring to their published paper.

Research in the field of cystic fibrosis has advanced significantly in recent years, and due to new CFTR-modulator therapeutics the prognosis for patients has improved greatly. T “In our research group, we study the interactions between beneficial and pathogenic bacteria in the lungs, and how these relationships influence lung infections and inflammation – particularly in relation to cystic fibrosis,” he explains and
adds: “Less than 50 years ago, cystic fibrosis was considered almost exclusively a childhood disease. Thanks to advances in research and novel medication, the life expectancy of patients has now risen to over 50 years.” Receiving the Adolf Windorfer Prize is a great source of motivation for the early-career scientist: “The prize is awarded annually by Mukoviszidose e.V. for outstanding achievements in research and therapy in the field of cystic fibrosis. It is a rare privilege for me to be this year’s recipient –it motivates and encourages me greatly.”

More information (In German)